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Abstract
Background: Regulatory T cells (Tregs), particularly the CD4
+CD25+Foxp3+ Tregs, down regulate immunity and
promote tumor cell growth by directly suppressing CD8+ and CD4+ T cells. Alternatively they can promote tumor
growth by generating interleukin-10 (IL-10) and transforming growth factor β (TGFβ) in situ, which help tumor cells
to evade the immune system.
Methods: In vivo tumor models were prepared via subcutaneous injection with a suspension of B16 melanoma
cells into the left upper flank of C57BL/6 J mice. The mice were randomized into five groups: radiotherapy (RT),
chemotherapy (CT), radiochemotherapy (RCT), Inteferon α (INFα) groups, and a control group. Flow cytometry was
used to determine the Tregs levels in the spleen and peripheral blood, and immunohistochemistry was performed
to determine the expression levels of TGFβ and IL-10 in the tumor microenvironment.
Results: Tumor weight was significantly reduced in the CT or RCT groups (40.91 % and 41.83 %, respectively), while
the reduction in tumor weight was relatively lower for the RT and IFNα groups (15.10 % and 13.15 %, respectively).
The flow cytometry results showed that the ratios of CD4+CD25+Foxp3+ Tregs to lymphocytes and CD4
+ cells in the
spleen and in peripheral blood were significantly decreased after treatment with IFNα (P < 0.05). Expression of TGFβ
and IL-10 in the tumor microenvironment in the CT and RT groups was higher compared with the control group
(P < 0.01), while the expression of TGFβ and IL-10 in the INFα group was not significantly different (P > 0.05).
Conclusions: The results show that INFα-2b inhibits cancer cell immune evasion by decreasing the levels of
CD4+CD25+Foxp3+ Tregs and suppressing the expression of TGFβ and IL-10 in the tumor microenvironment.
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Background
Although melanoma is not a common tumor worldwide
[1], it is the most lethal form of all skin cancers. In re-
cent years, its morbidity has increased more than any
other solid tumor. In 2012, 232,000 new melanoma
cases were reported throughout the world, accounting
for 2 % of all tumors. It was reported that there were
76,100 new melanoma cases, and 9719 deaths, in the
USA in 2014, accounting for 4.6 % and 1.7 % of all tu-
mors, respectively [2]. Other than classical therapies,
such as surgery, radiotherapy and chemotherapy, im-
munotherapy is playing an important role in the treat-
ment of melanoma. However, melanomas have been
found to evade the immune system, thus making them
a refractory type of cancer.
Regulatory T cells (Tregs), particularly CD4
+CD25
+Foxp3+ Tregs, down regulate immunity and promote
tumor cell growth [3]. Tregs can be recruited to the
microenvironment of melanoma because of the chemo-
taxis of chemokine (C-C Motif) Ligand 22 (CCL22) that is
produced by tumor cells [4]. As a result, infiltrated Tregs
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can exert suppressive effects on effector CD8+ and CD4+
T cells either through direct cell-to-cell contact [5, 6] or
indirectly by generating interleukin-10 (IL-10) and trans-
forming growth factor β (TGFβ) in situ [7–9], which helps
tumor cells to evade the immune system. Moreover, it has
been reported that Tregs can be directly induced by mel-
anoma cells, thus further suppressing the immune system
in the tumor microenvironment [10, 11].
TGFβ, which is a secreting protein that modulates cell
proliferation and differentiation, has dual effects in tumor
initiation and progression. In the early stage of tumorigen-
esis, TGFβ is a tumor suppressor, whereas in advanced tu-
mors, TGFβ promotes tumor angiogenesis, invasion,
metastasis, and immunosuppression [12]. Interleukin-10,
also known as human cytokine synthesis inhibitory factor,
is an anti-inflammatory cytokine which plays a critical role
in preventing an immune response and autoimmune path-
ologies [13]. Nevertheless, in tumorgenesis, IL-10 inhibits
the expression of antigen presenting cells (APCs) and fur-
ther prevents the dendritic cell (DC)-mediated transform-
ation of T cells into cytotoxic T cells (CTLs). It also affects
CD8+ T cells, which further promotes tumor initiation
and progression [14]. Both TGFβ and IL-10 in the tumor
microenvironment can be excreted by Tregs and tumor
cells, thus mediating the immunosuppressive effect of
Tregs [9]. As such, TGFβ and IL-10 can be regarded as
two significant immunosuppressors in the melanoma
microenvironment. However, the role of these two cyto-
kines in the tumor microenvironment still remains elusive
when challenged to differential clinical therapies.
As different treatment strategies have different ef-
fects on the tumor microenvironment, it is of interest
to investigate their effects and relevant mechanisms.
As such, in this study C57BL/6 J mice bearing mel-
anoma were used as tumor models and treated with
either radiotherapy (RT), chemotherapy (CT), radio-
chemotherapy (RCT), or intravenously administered
Inteferon α-2b (IFNα-2b). After treatment, the level
of Tregs in the spleen and in peripheral blood, and
the levels of TGFβ and IL-10 in the tumor micro-
environment were determined.
Methods
Mice model construction and group intervention
Thirty female C57BL/6 J mice were purchased from
Shanghai Slack laboratory Animal Co. Ltd (Shanghai,
China). Mice were 6-weeks old at the start of the experi-
ments, weighing 20 ± 2 g. B16 melanoma cells were har-
vested in their logarithmic growth phase and were made
into a single cell suspension (2.5 × 107 cells/mL). Each
mouse was then subcutaneously injected with 0.2 mL of
the cell suspension (about 5 × 106 cells) in their left
upper flank.
Thirty successfully B16 melanoma inoculated C57BL/
6 J mice were randomly divided into five groups: RT,
CT, RCT, INFα groups, and a control group, with six
mice per group. For each group, treatment was started
7 days after inoculation. Mice in the RT group were
given a single conformal treatment of 500 cGy of radi-
ation (source skin distance (SSD) = 100 cm, using a
5 cm × 5 cm module body filled lead-antimony alloy,
and 1.5-cm-thick physical tissue equivalent compensa-
tion filmed on the surface of the irradiated skin). Tail
vein injection and intraperitoneal injection (i.p.) of nor-
mal saline (NS, Zhejiang Shapuaisi Pharmaceutical
Limited, Pinghu, China) were used as the control inter-
vention for the IFNα and chemotherapy groups, re-
spectively [15, 16]. For the CT group, each animal was
intraperitoneally injected with 40 mg/kg dacarbazine
(DTIC, Nanjing Pharmaceutical Factory Co, Ltd, China)
daily from days 9 to 15, and NS was injected into the
tail vein as a control for IFNα. Mice in the IFNα group
were administrated with INFα-2b (10,000 U per mouse,
Schering-Plough Corporation, USA) via tail vein injec-
tion on days 7, 9, 11, 13 and 15, and NS was injected
i.p. as an alternative control for DTIC [17]. For the
RCT group, the mice were given identical treatments
synchronously with the RT and CT groups, with tail vein
injection of NS as a control treatment. For the control
group of mice, NS was administered via i.p. and tail vein
injection simultaneously with the CT and INFα groups.
On day 16, all mice had completed their treatments
and were sacrificed. Postocular blood (1 mL) was col-
lected before the animals were euthanized and the sam-
ples treated with 3.8 % sodium citrate to prevent
coagulation. The spleens were also excised and subcuta-
neous tumor xenografts were excised completely for fur-
ther examination.
Cell suspension preparation, antibody labeling and flow
cytometry
C57BL/6 J mice were euthanized by the cervical dis-
location method. Their spleens were excised on a clean
bench and ground on 200-mesh nylon before the fil-
trate was collected and centrifuged at 1.5 × 103 rpm for
5 min. The supernatant was discarded and the cells
were resuspended in phosphate buffered saline (PBS)
for further experiments.
Separating medium (2 mL Percoll, Santa Cruze,
Shanghai, China) was added to a centrifuge tube. Previ-
ously collected blood (2 mL) was then added to the
separating medium, and the samples centrifuged for
15 min at 3 × 103 rpm. The lymphocytes were then sep-
arated and transferred to another centrifuge tube and
spun for 5 min at 1.5 × 103 rpm, before they were resus-
pended with PBS for further experiments.
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Collected peripheral blood and spleen cell suspensions
were centrifuged at 1.5 × 103 rpm in order to collect
the cells in a 100 μL flow cytometry staining buffer
system. Mouse Regulatory T cell staining kit #1
(eBioscience, San Diego, CA, USA) was used to label
the cells as per the manufacturer’s instructions. Anti-
mouse CD4 (0.125 μg) and anti-mouse CD25 (0.06 μg)
were added to each reacting system and incubated in
the dark for 30 min at 4 °C. After surface antibody la-
beling, the cells were twice washed with flow cytome-
try staining buffer, before fixation/permeabilization
working solution (1 mL) was added to resuspend the
cells, before they were incubated overnight in the dark
at 4 °C. The cells were then twice washed with
permeabilization buffer, before 0.5 μg of Fc blocker
(CD16/32) was added, and the cells were incubated
again in the dark for 15 min at 4 °C. Finally, anti-
mouse/rat Foxp3 antibody (0.5 μg) was added and the
cells incubated in the dark for 30 min at 4 °C. The cells
were then twice washed with permeabilization buffer
before detection, using 500 μL of permeabilization buf-
fer to resuspend the cells. Flow cytometry was under-
taken using an Accuri C6 Flow Cytometer (BD
Biosciences, San Jose, CA, USA).
Lymphocyte clones were first selected from a FSC-A/
SSC-A scatterplot, then CD4+ T cells clones were selected
through a CD4 lymphocyte clone/SSC–A, and finally CD4
+CD25+Foxp3+ Treg cells were distinguished from CD4+
T cells by gating CD25/Foxp3 and homotype contrast with
Foxp3. The proportion of CD4+CD25+Foxp3+ Tregs to
CD4+ T cells and lymphocytes was calculated to evaluate
the level of CD4+CD25+Foxp3+ Tregs alteration, and the
results analyzed using t-tests.
Tumor tissue immunohistochemistry
Formalin-fixed paraffin sections were prepared and dried
overnight at 37 °C. Following dewaxing in xylene and re-
hydration with alcohols, endogenous peroxidase was
inactivated in 3 % H2O2 at 37 °C for 10 min. Microwave
antigen retrieval was completed using a citric acid buffer
(0.01 M, pH 6.0, Maixin Biotech, Fuzhou, China) and
cooled to room temperature. Immunohistochemistry
was performed with primary IL-10 (Abcam, ab34843,
Cambridge, UK) and TGFβ antibodies (Abcam, ab66043).
Slides were incubated with both primary antibodies at a
dilution of 1:100 overnight at 4 °C with PBS used as a
negative control, and balanced for 30 min at room
temperature. After washing with PBS, the slides were in-
cubated at a 1:200 dilution of goat anti-rabbit secondary
antibody (Abcam, GR101082-1) for 60 min at room
temperature. They were then washed with PBS, DAB sub-
strate kit (Zhongshanjinqiao Biotech, Beijing, China) and
used to develop the slides which were redyed with
hematoxylin (Sigma, St. Louis, MO, USA).
Three fields were randomly chosen for microscopic
study (×200) for each immunohistochemical slide. Each
tissue section was semi-quantitatively scored according
to the percentage of positive cells and the staining inten-
sity. We assigned the following proportion scores: 0 if
0–5 % of the tumor cells showed positive staining, 1 if
6–25 % of cells were stained, 2 if 26–50 % were stained,
3 if 51–75 % were stained, and 4 if over 75 % of the cells
were stained. We rated the intensity of staining on a
scale of 0 to 3: 0, negative; 1, weak; 2, moderate; and 3,
strong. We then combined the proportion and intensity
scores to obtain a total positive score (range, 0–12):
score 0 is negative, a score of 1 to 6 is weakly positive,
and a score of 7 to 12 is strongly positive.
Statistical analysis
All experimental data is presented as mean ± standard de-
viation, and analysis of variance (ANOVA) was performed
to compare the data of different groups using the statistical
analysis system 9.3 (SAS, Cary, NC, USA). A P value <0.05
was considered as statistically significant.
Results
RT, CT and IFNα significantly inhibit melanoma growth
C57BL/6 J mice were inoculated with B16 cells to pro-
duce an in vivo xenograft model of melanoma. The mice
were divided into five groups (n = 6), and treated with a
range of different therapies, including: RT, CT, RCT, and
IFNα. As shown in Fig. 1b, the tumor volumes of the
mice treated with different therapeutic regimens were all
smaller when compared with the tumor volumes of the
control group mice. This result indicates that tumor
growth can be significantly inhibited by conventional RT,
CT, RCT, and IFNα. When comparing tumor weights, we
calculated the tumor inhibition based on the mean weight
of each group (Fig. 1c, 1d). Tumor growth was better sup-
pressed when mice were given CT and RCT (40.91 % and
41.83 %, respectively) when compared with the tumors of
the RT and IFNα groups (15.10 % and 13.15 %, respect-
ively), as shown in Table 1.
IFNα significantly suppresses CD4+CD25+Foxp3+ Tregs
levels
Flow cytometry was used to determine Tregs levels in
the spleen and in peripheral blood of the mice after
completion of their treatments. In comparison to the
control group, the flow cytometry assay showed that the
mouse spleen levels of CD4+CD25+ Foxp3+ Tregs were
significantly down regulated in INFα group, compared
to the CD4+ T cells (P < 0.01) and to the lymphocyte
cells (P < 0.01). The decrease in CD4+CD25+Foxp3+
Tregs levels of the CT group was significant when com-
pared with the CD4+ T cells (P < 0.05), but not
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significant when compared with the lymphocytes
(P > 0.05) (Fig. 2b, 2c).
The results for the peripheral blood samples showed a
significant decrease in the IFNα treatment group for both
CD4+CD25+Foxp3+ Tregs compared with the CD4
+ T cells
and compared with the lymphocytes (P < 0.05), although
there was no significant change in the CD4+CD25+Foxp3+
Tregs levels for the RT, CT and RCT groups (Fig. 3). The
data indicates that IFNα-based immunotherapy can sig-
nificantly down regulate the level of CD4+CD25+Foxp3+
Tregs while RT and CT have little effect.
RT and CT upregulate expression of TGFβ and IL-10 in
tumor microenvironment
To investigate the changes in TGFβ and IL-10 levels in
the tumor microenvironment, immunohistochemistry
was used to examine TGFβ and IL-10 expression in the
xenografts. As shown in Fig. 4a, the expression of TGFβ
and IL-10 in RT and CT treated mice were much higher
when compared to the levels in the tumors of the con-
trol group. The results showed that the expression levels
in the CT were significantly different to the control
group for TGFβ (p < 0.01) and IL-10 (p < 0.001). In
Fig. 1 Changes in the tumors after treatment with different therapies. a C57BL/6 J mice and excised tumors from each group. b Volumes of the
tumors treated with radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RCT) and IFNα were significantly smaller than those of the control
group, p < 0.05. V = 4/3πabc, a. major radius, b. minor radius, c. radius perpendicular to minor axis, measured by ultrasound. c Excised tumors
were weighed using an analytical balance. Tumor weights were reduced significantly in the CT and RCT groups, while only mildly reduced in the
RT and IFNα groups. d. Tumor inhibition rate ((Wcontrol-Wtreatment)/Wcontrol × 100 %) after treatment based on the tumor mass
Table 1 Melanoma tumor mass after treatment with different regimens
Groups Control Radiotherapy Chemotherapy Chemoradio- INFα
Treatment None 6 MeV X-ray 500 cGy DTIC 40 mg/kg,D9-15 X-ray + DTIC IFNα-2b 10000U D7,9,11,13,15
Number of mice 6 6 6 6 6
Weight of mass (g) 3.70 ± 0.94 3.14 ± 0.90 2.18 ± 0.77 2.15 ± 1.03 3.21 ± 1.86
p value 0.366 0.024 0.039 0.617
Volume of mass (cm3) 4.56 ± 0.94 2.60 ± 0.68 2.66 ± 1.18 2.10 ± 1.12 2.44 ± 1.37
p value 0.005 0.023 0.006 0.021
Inhibition rate (%) N/A 15.1 40.91 41.83 13.15
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addition, RT was found to increase the expression of IL-
10 in the surrounding cancer cells (p < 0.01) and TGFβ
expression was also upregulated, although there was no
significant difference (p > 0.05) when compared with the
control group (Fig. 4b, 4c). In contrast to the RT and CT
groups, positive scores arising from the IFNα treatment
indicated no significant alteration in TGFβ and IL-10 ex-
pression levels (p > 0.05, Fig. 4).
Discussion
In the treatment of melanoma, RT, CT, and interferon
are all common adjuvant therapies after surgery. But
while many in vitro and in vivo studies have shown that
melanoma growth can be slowed with RT or CT ther-
apy, little clinical success has been achieved. In addition,
there is little known about the benefit of immunothera-
peutic regimens either in basic studies or clinical re-
search. This is important to determine as research has
shown that different immune mechanisms appear to play
a critical role in the biological behavior of melanoma.
The purpose of this study was to examine the effect of
different therapeutic regimens on the immune status and
microenvironment of the tumors, in particular how the dif-
ferent treatments affected the levels of CD4+CD25+Foxp3+
Tregs, TGFβ, and IL-10.
The results of this study show that melanoma growth
can be significantly inhibited by many of the examined
therapies including RT, CT and IFNα. Despite the varying
results of the tumor inhibition, the most effective was for
the CT and RCT groups when compared with the RT and
immunotherapy groups. From this we hypothesized that
results are a function of the differing mechanisms under-
lying the treatments. The drug DTIC exerts its effect
through indirect inhibition of cell metabolism and direct
cytotoxicity. While RT has a limited ability to suppress
melanoma growth, it may be used synergistically with CT
Fig. 2 Flow cytometry assay of mice spleen tissue. a Gating strategies of CD4+ T cells and CD25+FOXP3+ Tregs for spleen tissue. b and c
Proportion of Tregs to CD4
+ T cells and lymphocytes in the spleen. * indicates P < 0.05 and ** indicates P < 0.01 compared with the control group
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to kill cancer cells. IFNα therapy is able to modulate the
immune system, and through this, slow the growth of
melanoma, although its ability to directly affect tumor
growth is weak. We have observed the clinical efficacy of
different treatments during practice, yet the effect of im-
munotherapy is relatively mild and it takes time for the
treatment to take effect. We hypothesize that RT and CT
generally enhance immunosuppression and decrease the
immune response. The results of this work have revealed
that a decrease of CD4+CD25+Foxp3+ Tregs in the spleens
of the mice after INFα treatment was most prominent
compared with the levels found in mice treated with RT
and CT. Also, a significant decrease in the CD4+CD25
+Foxp3+ Tregs levels in peripheral blood was detected in
the INFα group, as revealed by flow cytometry (p < 0.05).
These results suggest that immunotherapy with IFNα has
the ability of down regulate CD4+CD25+Foxp3+ Tregs, yet
the influence of RT and CT on CD4+CD25+Foxp3+ Tregs
levels is negligible.
It has recently been reported that IFNα can induce the
MAPK/ERK (mitogen-activated protein kinases/extracel-
lular signal-regulated kinases)-mediated phosphodiester-
ase four activation, and negatively affect cAMP in CD4
+CD25+Foxp3+ Tregs, thus suppressing the function of
Tregs [18]. At the same time, the Jak-Stat1 (Janus Kin-
ase- Signal transducers and activators of transcription 1)
pathway can be stimulated by IFNα, which consequently
activates effector T cells, natural killer (NK) cells, and
dendritic cells, thereby indirectly enhancing the cyto-
toxic effect on tumor cells [15, 19–21]. Studies by Ster-
gios et al. have suggested an indirect immunoregulatory
mechanism of high-dose IFNα-2b which activates host
immune cells to increase the cytocidal effect on cancer
cells [21]. In this study, we have demonstrated that INFα
is capable of significantly decreasing CD4+CD25+Foxp3+
Tregs levels in the spleen and in peripheral blood, sug-
gesting the immunomodulatory ability of INFα is to
down regulate CD4+CD25+Foxp3+ Tregs. Many other
Fig. 3 Flow cytometry analysis of mice peripheral blood. a Gating strategies of CD4+ T cells and CD25+FOXP3+ Tregs for peripheral blood. b and
c Proportions of Tregs to CD4
+ T cells and lymphocytes in peripheral blood. * indicates P < 0.05 and ** indicates P < 0.01 compared with the
control group
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studies have revealed that the ratio of CD4+CD25+Foxp3
+ Tregs to lymphocytes can be significantly upregulated
in peripheral blood, in the spleen and in the lymphoids,
and CD4+CD25+Foxp3+ Tregss are resistant to γ-
radiation [16, 22]. Our study has also showed the radio-
resistance of CD4+CD25+ Foxp3+ Tregs to a certain ex-
tent, particularly CD4+CD25+ Foxp3+ Tregs in peripheral
blood. Accordingly, we hypothesize that comprised
Fig. 4 Immunohistochemistry and positive scores of TGFβ and IL-10 in the tumor microenvironment. a. Immunohistochemistry graphs of tumor
xenografts in C57BL/6 J mice, post treatment. Extensive expression of TGFβ and IL-10 could be detected in the area surrounding the melanoma
cells post radiotherapy and chemotherapy, while IFNα had little effect on the expression of TGFβ and IL-10. b and c Immunohistochemistry
positive scores of TGFβ and IL-10. * indicates P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001 compared with the control group
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lymphocytes exposed to irradiation and radio-resistant
CD4+CD25+ Foxp3+ Tregs that infiltrate into the micro-
environment have been implicated in the immunosup-
pression of those patients given radiotherapy. Several
other studies have suggested that the immune response
of tumor cells can be modulated by fludarabine, pacli-
taxel and cyclophosphamide, by decreasing or depleting
CD4+CD25+Foxp3+ Tregs [23–25]. However, Tohyama
et al. [17] have reported that chemotherapeutic agents,
such as DTIC, have the ability to impair immunity by in-
creasing CD4+CD25+Foxp3+ Tregs and decreasing ef-
fector cells, which is consistent with our results. To this
end, further studies are needed to investigate the clinical
efficacy of different drugs on physical immunity.
Our study also used immunohistochemistry to detect
the expression levels of TGFβ and IL-10 in the tumor
microenvironment. The results showed that expression
of TGFβ and IL-10 was significantly upregulated around
tumor cells post RT, CT and RCT, indicating high im-
munosuppression in the tumor microenvironment. It has
been reported that TGFβ and IL-10 are required for CD4
+CD25+Foxp3+ Tregs mediated immune suppression,
which inactivates CD8+ T cells and NK cells [9, 14, 26, 27].
The combined results of this work and others indicates
that increased levels of TGFβ and IL-10 post RT and CT,
inhibit physical immunity as a result of RT and CT turning
CD4+CD25+Foxp3+ Tregs as predominant immune cells
among lymphocyte population. From this, they suppress
the recruitment of other effector cells, such as CTLs and
NK cells, which therefore helps cancer cells to evade the
immune system. In contrast to RT and CT, no significant
alterations of TGFβ and IL-10 levels in the microenviron-
ment were observed after IFNα-based immunotherapy.
Conclusions
The present study showed that expression of Tregs can be
down regulated by IFNα, which reverses immunosuppres-
sion and makes the cancer cells more susceptible to treat-
ment. The reason for why no significant down regulation
of TGFβ and IL-10 was detected during IFNα treatment
may due to short observing time, which also parallels the
response processes of IFNα in clinical utilization. For dif-
ferential therapeutic regimens have varying effects on
physical immunity, the immune condition of patients post
therapy should be considered when developing new treat-
ment regimens.
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